197 related articles for article (PubMed ID: 36403818)
1. Anakinra or high-dose corticosteroids in COVID-19 pneumonia patients who deteriorate on low-dose dexamethasone: an observational study of comparative effectiveness.
Langer-Gould A; Xu S; Myers LC; Chen A; Greene JD; Creekmur B; Bruxvoort K; Adams JL; Liu V; Gould MK
Int J Infect Dis; 2023 Jan; 126():87-93. PubMed ID: 36403818
[TBL] [Abstract][Full Text] [Related]
2. High-dose corticosteroids in patients hospitalized for COVID-19 pneumonia: an observational study of comparative effectiveness.
Langer-Gould A; Xu S; Myers LC; Chen A; Greene JD; Creekmur B; Bruxvoort K; Adams JL; Liu V; Gould MK
Int J Infect Dis; 2022 Dec; 125():184-191. PubMed ID: 36404464
[TBL] [Abstract][Full Text] [Related]
3. Characteristics and clinical outcome in 312 patients with moderate to severe pneumonia due to SARS-COV-2 and hyperinflammation treated with anakinra and corticosteroids: A retrospective cohort study.
Aomar-Millán IF; de Victoria-Carazo JM; Fernández Reyes D; Torres-Parejo Ú; Pérez Fernández L; Martínez-Diz S; Ceballos Torres A; López Gómez J; Bizzarri F; Raya Álvarez E; Salvatierra J
PLoS One; 2023; 18(3):e0283529. PubMed ID: 36961847
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of corticosteroid treatment for hospitalized patients with severe COVID-19: a multicentre study.
Bartoletti M; Marconi L; Scudeller L; Pancaldi L; Tedeschi S; Giannella M; Rinaldi M; Bussini L; Valentini I; Ferravante AF; Potalivo A; Marchionni E; Fornaro G; Pascale R; Pasquini Z; Puoti M; Merli M; Barchiesi F; Volpato F; Rubin A; Saracino A; Tonetti T; Gaibani P; Ranieri VM; Viale P; Cristini F;
Clin Microbiol Infect; 2021 Jan; 27(1):105-111. PubMed ID: 32971254
[TBL] [Abstract][Full Text] [Related]
5. Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study.
Bozzi G; Mangioni D; Minoia F; Aliberti S; Grasselli G; Barbetta L; Castelli V; Palomba E; Alagna L; Lombardi A; Ungaro R; Agostoni C; Baldini M; Blasi F; Cesari M; Costantino G; Fracanzani AL; Montano N; Monzani V; Pesenti A; Peyvandi F; Sottocorno M; Muscatello A; Filocamo G; Gori A; Bandera A
J Allergy Clin Immunol; 2021 Feb; 147(2):561-566.e4. PubMed ID: 33220354
[TBL] [Abstract][Full Text] [Related]
6. Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study.
Borie R; Savale L; Dossier A; Ghosn J; Taillé C; Visseaux B; Jebreen K; Diallo A; Tesmoingt C; Morer L; Goletto T; Faucher N; Hajouji L; Neukirch C; Phillips M; Stelianides S; Bouadma L; Brosseau S; Ottaviani S; Pluvy J; Le Pluart D; Debray MP; Raynaud-Simon A; Descamps D; Khalil A; Timsit JF; Lescure FX; Descamps V; Papo T; Humbert M; Crestani B; Dieude P; Vicaut E; Zalcman G;
PLoS One; 2020; 15(12):e0243961. PubMed ID: 33326457
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pulse-dose and high-dose corticosteroids with no corticosteroid treatment for COVID-19 pneumonia in the intensive care unit.
Yaqoob H; Greenberg D; Hwang F; Lee C; Vernik D; Manglani R; Wang Z; Murad MH; Chandy D; Epelbaum O
J Med Virol; 2022 Jan; 94(1):349-356. PubMed ID: 34542192
[TBL] [Abstract][Full Text] [Related]
8. Tocilizumab versus anakinra in COVID-19: results from propensity score matching.
Arcani R; Correard F; Suchon P; Kaplanski G; Jean R; Cauchois R; Leprince M; Arcani V; Seguier J; De Sainte Marie B; Andre B; Koubi M; Rossi P; Gayet S; Gobin N; Garrido V; Weiland J; Jouve E; Couderc AL; Villani P; Daumas A
Front Immunol; 2023; 14():1185716. PubMed ID: 37304271
[TBL] [Abstract][Full Text] [Related]
9. Corticosteroid use in viral pneumonia: experience so far and the dexamethasone breakthrough in coronavirus disease-2019.
Rafiullah M; Siddiqui K
J Comp Eff Res; 2020 Dec; 9(18):1247-1254. PubMed ID: 33245242
[TBL] [Abstract][Full Text] [Related]
10. The Use of High-Dose Corticosteroids Versus Low-Dose Corticosteroids With and Without Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome.
Katz A; Altshuler D; Papadopoulos J; Amoroso N; Goldenberg R; Tarras E; Krolikowski K; Hagedorn J; Fridman D; Chen XJC; Iturrate E; Brosnahan SB
Ann Pharmacother; 2023 Jan; 57(1):5-15. PubMed ID: 35590468
[TBL] [Abstract][Full Text] [Related]
11. Anakinra in hospitalized COVID-19 patients guided by baseline soluble urokinase plasminogen receptor plasma levels: A real world, retrospective cohort study.
Segala FV; Rando E; Salvati F; Negri M; Catania F; Sanmartin F; Murri R; Giamarellos-Bourboulis EJ; Fantoni M
PLoS One; 2023; 18(4):e0273202. PubMed ID: 37014833
[TBL] [Abstract][Full Text] [Related]
12. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
Aomar-Millán IF; Salvatierra J; Torres-Parejo Ú; Faro-Miguez N; Callejas-Rubio JL; Ceballos-Torres Á; Cruces-Moreno MT; Gómez-Jiménez FJ; Hernández-Quero J; Anguita-Santos F
Intern Emerg Med; 2021 Jun; 16(4):843-852. PubMed ID: 33400157
[TBL] [Abstract][Full Text] [Related]
13. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab.
Langer-Gould A; Smith JB; Gonzales EG; Castillo RD; Figueroa JG; Ramanathan A; Li BH; Gould MK
Int J Infect Dis; 2020 Oct; 99():291-297. PubMed ID: 32768693
[TBL] [Abstract][Full Text] [Related]
14. Low-Dose Tocilizumab With High-Dose Corticosteroids in Patients Hospitalized for COVID-19 Hypoxic Respiratory Failure Improves Mortality Without Increased Infection Risk.
Brosnahan SB; Chen XJC; Chung J; Altshuler D; Islam S; Thomas SV; Winner MD; Greco AA; Divers J; Spiegler P; Sterman DH; Parnia S
Ann Pharmacother; 2022 Mar; 56(3):237-244. PubMed ID: 34180274
[TBL] [Abstract][Full Text] [Related]
15. Comparative Survival Analysis of Immunomodulatory Therapy for Coronavirus Disease 2019 Cytokine Storm.
Narain S; Stefanov DG; Chau AS; Weber AG; Marder G; Kaplan B; Malhotra P; Bloom O; Liu A; Lesser ML; Hajizadeh N;
Chest; 2021 Mar; 159(3):933-948. PubMed ID: 33075378
[TBL] [Abstract][Full Text] [Related]
16. Can Anakinra and corticosteroid treatment be an effective option in pregnant women with severe Covid-19?
Karakaş Ö; Erden A; Ünlü S; Erol SA; Goncu Ayhan Ş; Özdemir B; Tanacan A; Ozden Tokalioglu E; Ateş İ; Moraloğlu Tekin Ö; Omma A; Şahin D; Küçükşahin O
Women Health; 2021 Oct; 61(9):872-879. PubMed ID: 34551674
[TBL] [Abstract][Full Text] [Related]
17. Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19.
Liu Z; Li X; Fan G; Zhou F; Wang Y; Huang L; Yu J; Yang L; Shang L; Xie K; Xu J; Huang Z; Gu X; Li H; Zhang Y; Wang Y; Huang Z; Cao B
Clin Microbiol Infect; 2021 Jan; 27(1):112-117. PubMed ID: 33007478
[TBL] [Abstract][Full Text] [Related]
18. Association between different corticosteroid regimens used in severe SARS-CoV-2 infection and short-term mortality: retrospective cohort study.
González-Castro A; Fernandez A; Cuenca-Fito E; Peñasco Y; Ceña J; Rodríguez Borregán JC
Rev Esp Anestesiol Reanim (Engl Ed); 2024 May; 71(5):379-386. PubMed ID: 38395302
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Survival by IL-6 in a Randomized Placebo-Controlled Trial of Anakinra in COVID-19 Cytokine Storm.
Jackson LE; Khullar N; Beukelman T; Chapleau C; Kamath A; Cron RQ; Chatham WW
Viruses; 2023 Sep; 15(10):. PubMed ID: 37896812
[TBL] [Abstract][Full Text] [Related]
20. An open label trial of anakinra to prevent respiratory failure in COVID-19.
Kyriazopoulou E; Panagopoulos P; Metallidis S; Dalekos GN; Poulakou G; Gatselis N; Karakike E; Saridaki M; Loli G; Stefos A; Prasianaki D; Georgiadou S; Tsachouridou O; Petrakis V; Tsiakos K; Kosmidou M; Lygoura V; Dareioti M; Milionis H; Papanikolaou IC; Akinosoglou K; Myrodia DM; Gravvani A; Stamou A; Gkavogianni T; Katrini K; Marantos T; Trontzas IP; Syrigos K; Chatzis L; Chatzis S; Vechlidis N; Avgoustou C; Chalvatzis S; Kyprianou M; van der Meer JW; Eugen-Olsen J; Netea MG; Giamarellos-Bourboulis EJ
Elife; 2021 Mar; 10():. PubMed ID: 33682678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
